Abbott Reports Interim Results From Phase III Open-Label Study Of Investigational Treatment For Advanced Parkinson’s …

Abbott Reports Interim Results From Phase III Open-Label Study Of Investigational Treatment For Advanced Parkinson’s … Interim efficacy and safety results from a long-term, 54-week, Phase III open-label study of Abbott’s investigational treatment for advanced Parkinson’s disease showed that patients treated with levodopa-carbidopa intestinal gel (LCIG) for 12 weeks reported a decrease in “off” time […]

Abbott Reports Interim Results From Phase III Open-Label Study Of Investigational Treatment For Advanced Parkinson’s …
Interim efficacy and safety results from a long-term, 54-week, Phase III open-label study of Abbott’s investigational treatment for advanced Parkinson’s disease showed that patients treated with levodopa-carbidopa intestinal gel (LCIG) for 12 weeks reported a decrease in “off” time and an increase in “on” time without troublesome dyskinesias.

Read more on BioresearchOnline

Related posts:

  1. Web.com Reports Fourth Quarter and Full Year 2010 Financial Results
  2. Web.com Reports First Quarter 2011 Financial Results
  3. Immunomedics Awarded U.S. Patent for Veltuzumab, Company’s Humanized Anti-CD20 Antibody in Advanced Clinical Testing
  4. Banro’s Phase 1 Mining of the Oxide Cap at Twangiza Indicates Annual Gold Production of 119,303 Ounces at Total Cash …
  5. Case study help:

Popular Posts


Leave Your Response

* Name, Email, Comment are Required